Rifat Pamukcu
Independent DirectorDr. Rifat Pamukcu, also known as Rif, M.D., serves as an Independent Director at Aprea Therapeutics Inc. since May 16, 2022. He serves as a Director at Syantra Inc. He is currently director, President and Chief Executive Officerof RXMP Therapeutics, Incorporated since 2016. He has been Chief Medical Advisor of Aprea Therapeutics, Inc (formerly known as Atrin Pharmaceuticals LLC) since September 8, 2016. Dr. Pamukcu serves as Chairman, Chief Executive Officer and President of Midway Pharmaceuticals Inc. since 2005. Dr. Pamukcu served as Executive Vice President of Research and Development at Cell Pathways, Inc. since July 2000 and as Chief Scientific Officer since 1993. Dr. Pamukcu co-founded Cell Pathways, Inc. and served as its Senior Vice President from 1997 to July 2000. He directed the basic science, preclinical drug development, clinical research, regulatory programs and various aspects of chemical scale-up and manufacturing over the last decade. During his fellowship, he co-founded Cell Pathways with one of his patients, Mr. Floyd Nichols, who suffered from Familial Polyposis, the disease which CPIs first drug was designed to treat. Dr. Pamukcu serves as Chairman of Glyconix Corp. Dr. Pamukcu served as a Director of Cell Pathways, Inc. since September 2000, Dr. Pamukcu has been a member of the Advisory Council to the National Prostate Cancer Coalition, the GI Oncology Task Force of the American Gastroenterological Association, Executive Steering Committee of the Gastroenterology Research Group and Scientific Advisory Board of the Hereditary Colon Cancer Association. He was one of twenty-five invited members to the Clinical Trials Summit, a high level think-tank directed at changing the paradigm by which breast cancer drugs are developed, convened by the National Breast Cancer Coalition. He was an invited speaker at the first International GI Malignancy Conference in Israel, a meeting established through the joint efforts of President Bill Clinton and the Israeli Prime Minister. He was most recently honored with addressing the international think-tank of the British Gastroenterology Society, Royal Society of Medicine on GI malignancies and their prevention. He is a Managing Partner of Corami Limited Liability Company since 2016. Since 1985, Dr. Pamukcu has authored or co-authored over 110 journal articles, book chapters and abstracts in the fields of gastroenterology, cancer, cancer chemoprevention and signal transduction systems. He is an inventor on over 280 issued or pending patents in the areas of drug discovery and development of agents for cancer prevention, cancer chemotherapeutics and inflammatory bowel disease. Dr. Pamukcu subsequently was appointed Assistant Professor of Medicine at the University of Cincinnati, where, as a consultant, he nurtured Cell Pathways during its infancy. In 1993, Dr. Pamukcu became adjunct faculty at the University of Cincinnati (a position he held until 1995) so that he could devote his efforts full-time to Cell Pathways. He completed his residency in Internal Medicine at Rush-Presbyterian St. Lukes Medical Center. He was a postdoctoral fellow from 1986 to 1989 in the Division of Gastroenterology at the University of Chicago. Dr. Pamukcu received his B.A. degree in Biology from the Johns Hopkins University in 1979 and his M.D. degree from the University of Wisconsin School of Medicine in 1983.
Positions
- Company NameAprea Therapeutics, Inc.Stock CodeAPREPositionIndependent DirectorColleagues
- OGOren GiladCo-Founder, CEO, President & Director
- RPRichard PetersIndependent Chairperson of the Board
- JPJohn P. HamillSenior VP, CFO, Principal Accounting Officer & Secretary
- LBLars B. AbrahmsenSenior VP & Chief Scientific Officer
- BWBrian WileySenior Vice President of Corporate Development & Strategy
- MAMichel AfarganHead of Pharmacology Development
- MJMichael J. GrissingerIndependent Director
- JBJohn B. HennemanIndependent Director
